Literature DB >> 1736881

Expression, purification and characterization of a mouse-human chimeric antibody and chimeric Fab' fragment.

D J King1, J R Adair, S Angal, D C Low, K A Proudfoot, J C Lloyd, M W Bodmer, G T Yarranton.   

Abstract

B72.3 is a mouse monoclonal antibody against a tumour-associated antigen, TAG72, which recognizes breast, ovarian and colorectal tumour tissue. A mouse-human chimeric version of B72.3 has been expressed in Chinese-hamster ovary cells. This molecule has the binding specificity of B72.3 and constant regions from human IgG4. The chimeric B72.3 assembles to intact IgG and recognizes TAG72 as well as B72.3 in competitive binding assays. A proportion of the chimeric B72.3 (approx. 10%) does not form inter-heavy-chain disulphide bonds but still assembles into the IgG tetramer. This appears to be a general property of human IgG4 molecules. Co-expression of the chimeric light chain with a chimeric Fd' gene resulted in the expression of functional Fab'. Very little F(ab')2 is produced, although the Fab' can be oxidized to the dimeric F(ab')2 in vitro. The production of Fab' and F(ab')2 by this method is an attractive alternative to proteolytic digestion of IgG. The ability to produce these molecules in large quantities will allow the production and testing of a range of anti-tumour antibody and antibody fragment conjugates.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1736881      PMCID: PMC1130685          DOI: 10.1042/bj2810317

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  30 in total

1.  Influence of the hinge region on complement activation, C1q binding, and segmental flexibility in chimeric human immunoglobulins.

Authors:  L K Tan; R J Shopes; V T Oi; S L Morrison
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

2.  Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3.

Authors:  V G Johnson; J Schlom; A J Paterson; J Bennett; J L Magnani; D Colcher
Journal:  Cancer Res       Date:  1986-02       Impact factor: 12.701

Review 3.  Radioimmunoscintigraphy in tumour identification.

Authors:  K E Britton; M Granowska
Journal:  Cancer Surv       Date:  1987

4.  Differential reactivity of monoclonal antibodies with human colon adenocarcinomas and adenomas.

Authors:  D Stramignoni; R Bowen; B F Atkinson; J Schlom
Journal:  Int J Cancer       Date:  1983-05-15       Impact factor: 7.396

5.  An in vitro system for studying the kinetics of interchain disulfide bond formation in immunoglobulin G.

Authors:  J G Petersen; K J Dorrington
Journal:  J Biol Chem       Date:  1974-09-10       Impact factor: 5.157

6.  Purification and composition of the human tumor-associated glycoprotein (TAG-72) defined by monoclonal antibodies CC49 and B72.3.

Authors:  D G Sheer; J Schlom; H L Cooper
Journal:  Cancer Res       Date:  1988-12-01       Impact factor: 12.701

7.  Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3.

Authors:  A Thor; N Ohuchi; C A Szpak; W W Johnston; J Schlom
Journal:  Cancer Res       Date:  1986-06       Impact factor: 12.701

8.  Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy.

Authors:  S M Larson; J A Carrasquillo; K A Krohn; J P Brown; R W McGuffin; J M Ferens; M M Graham; L D Hill; P L Beaumier; K E Hellström
Journal:  J Clin Invest       Date:  1983-12       Impact factor: 14.808

9.  Expression in COS cells of a mouse-human chimaeric B72.3 antibody.

Authors:  N Whittle; J Adair; C Lloyd; L Jenkins; J Devine; J Schlom; A Raubitschek; D Colcher; M Bodmer
Journal:  Protein Eng       Date:  1987-12

10.  Improved radioimaging and tumor localization with monoclonal F(ab')2.

Authors:  R L Wahl; C W Parker; G W Philpott
Journal:  J Nucl Med       Date:  1983-04       Impact factor: 10.057

View more
  17 in total

1.  Novel size-independent modeling of the dilute solution conformation of the immunoglobulin IgG Fab' domain using SOLPRO and ELLIPS.

Authors:  B Carrasco; J G de la Torre; O Byron; D King; C Walters; S Jones; S E Harding
Journal:  Biophys J       Date:  1999-12       Impact factor: 4.033

2.  World Bispecific Antibody Summit, September 27-28, 2011, Boston, MA.

Authors:  Eugen Dhimolea; Janice M Reichert
Journal:  MAbs       Date:  2012 Jan-Feb       Impact factor: 5.857

3.  Normal human immunoglobulin G4 is bispecific: it has two different antigen-combining sites.

Authors:  J Schuurman; R Van Ree; G J Perdok; H R Van Doorn; K Y Tan; R C Aalberse
Journal:  Immunology       Date:  1999-08       Impact factor: 7.397

4.  Intrachain disulfide bond in the core hinge region of human IgG4.

Authors:  J W Bloom; M S Madanat; D Marriott; T Wong; S Y Chan
Journal:  Protein Sci       Date:  1997-02       Impact factor: 6.725

Review 5.  IgG4 breaking the rules.

Authors:  Rob C Aalberse; Janine Schuurman
Journal:  Immunology       Date:  2002-01       Impact factor: 7.397

Review 6.  Disulfide bond structures of IgG molecules: structural variations, chemical modifications and possible impacts to stability and biological function.

Authors:  Hongcheng Liu; Kimberly May
Journal:  MAbs       Date:  2012 Jan-Feb       Impact factor: 5.857

7.  Expression, purification and characterization of B72.3 Fv fragments.

Authors:  D J King; O D Byron; A Mountain; N Weir; A Harvey; A D Lawson; K A Proudfoot; D Baldock; S E Harding; G T Yarranton
Journal:  Biochem J       Date:  1993-03-15       Impact factor: 3.857

Review 8.  Pathophysiology of autoimmune pancreatitis.

Authors:  Raffaele Pezzilli; Nico Pagano
Journal:  World J Gastrointest Pathophysiol       Date:  2014-02-15

9.  A comprehensive analysis of novel disulfide bond introduction site into the constant domain of human Fab.

Authors:  Hitomi Nakamura; Moeka Yoshikawa; Naoko Oda-Ueda; Tadashi Ueda; Takatoshi Ohkuri
Journal:  Sci Rep       Date:  2021-06-21       Impact factor: 4.379

10.  Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy.

Authors:  D J King; P Antoniw; R J Owens; J R Adair; A M Haines; A P Farnsworth; H Finney; A D Lawson; A Lyons; T S Baker
Journal:  Br J Cancer       Date:  1995-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.